Compare AngloGold Ashanti Limited (AU) vs Cigna Corp (CI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Cigna Corp — how do they compare? AngloGold Ashanti Limited trades at $97.6 (market cap $49.28B), while Cigna Corp trades at $272.72 (market cap $73.56B). The key difference: Cigna Corp is the larger of the two by market cap, and AngloGold Ashanti Limited pays the higher dividend (4.64%). Which is the better fit depends on your goals.
| AU | CI | |
|---|---|---|
Market Cap | $49.28B | $73.56B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $311.00 |
52-Week Low | $52.15 | $244.41 |
Enterprise Value | $48.29B | $98.27B |
Dividend Yield | 4.64% | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $97.89, up 0.66% with strong bullish momentum from moving averages. The stock shows robust fundamentals with 32.19% net income margin and 46.5% ROE, supported by rising gold prices and production growth. Recent Q2 2026 earnings beat expectations with $727 million free cash flow, while the company maintains a $2 billion buyback program. Technical indicators show overbought conditions with RSI at 79.27, but institutional interest remains strong with multiple recent position increases.
Outlook remains positive with analyst consensus target of $120.33 (23% upside) and 64% buy ratings. Key catalysts include H2 production growth and shareholder returns, though risks include gold price volatility and operational challenges. The stock trades at reasonable valuations (P/E 13.06, EV/EBITDA 7.58) with improving balance sheet strength (debt-to-asset ratio declining to 15.59%).
Cigna (CI) trades at $278.15, showing slight daily weakness but maintaining a strong fundamental profile with consistent earnings beats. The stock appears undervalued with a P/E of 11.51 and P/S of 0.26, while technical indicators show bearish momentum near key support at $271. Recent Q2 2026 results exceeded expectations with EPS of $7.78 versus $7.60 estimates, driving management's raised full-year guidance.
Cigna presents a compelling value opportunity with analyst consensus pointing to 22% upside to the $338.90 price target. However, near-term technical pressure and competitive healthcare margins require monitoring. The company's stable dividend payments and institutional accumulation support long-term confidence despite current bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
